Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm

Pharmaceutical Research

Volumn 16, Issue 3, 1999, Pages 342-349

  Krynetski, Eugene Y ^a,b   Evans, William E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Genetic polymorphism; Genotyping; Mercaptopurine; Thioguanine; Thiopurine S methyltransferase

Indexed keywords

AZATHIOPRINE; DRUG METABOLIZING ENZYME; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ALLELE; AUTOSOME; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME POLYMORPHISM; GENE ISOLATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; LEUKEMIA; METHYLATION; MOLECULAR CLONING; NORTHERN BLOTTING; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS;

6-MERCAPTOPURINE; AMINO ACID SEQUENCE; ANTIMETABOLITES, ANTINEOPLASTIC; HUMANS; METHYLTRANSFERASES; MOLECULAR SEQUENCE DATA; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0032931005     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011909315614     Document Type: Review

References (56)

1. 1. W. Kalow and D. R. Gunn. Some statistical data on atipical cholinesterase of human serum. Ann. Hum. Genet. 23:239-250 (1998).
2. 2. D. M. Grant. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 3:45-50 (1993).
3. 3. U. A. Meyer and U. M. Zanger. Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann. Rev. Pharmacol. Toxicol. 37:269-296 (1997).
4. 4. M. Eichelboum and A. S. Gross. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharm. Ther. 46: 377-394 (1990).
5. 5. A. V. Boddy and M. J. Ratain. Pharmacogenetics in cancer etiology and chemotherapy. Clin. Cancer Res. 3:1025-1030 (1997).
6. 6. K. D. Tew. Genetic polymorphisms of detoxification enzymes. Cell. Pharmacol. 3:143-152 (1998).
7. 7. H. M. Lachman, D. F. Papolos, T. Saito, Y. M. Yu, C. L. Szumlanski, and R. M. Weinshilboum. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatrie disorders. Pharmacogenetics 6:243-250 (1996).
8. 8. E. Y. Krynetski, H. L. Tai, C. R. Yates, M. Y. Fessing, T. Loennechen, J. D. Schuetz, M. V. Relling, and W. E. Evans. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 6:279-290 (1996).
9. 9. E. Y. Krynetski and W. E. Evans. Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet. 63:11-16 (1998).
10. 10. E. Beutler, T. Gelbart, and A. Demina. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA 95:8170-8174 (1998).
11. 11. C. N. Remy. Metabolism of thiopyrimidines and thiopurines: S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J. Biol. Chem. 238:1078-1084 (1963).
12. 12. R. M. Weinshilboum and S. L. Sladek. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32:651-662 (1980).
13. 13. C. L. Szumlanski, R. Honchel, M. C. Scott, and R. M. Weinshilboum. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2:148-159 (1992).
14. 14. H. L. McLeod, J. S. Lin, E. P. Scott, C. H. Pui, and W. E. Evans. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin. Pharmacol. Ther. 55:15-20 (1994).
15. 15. C. R. Yates, E. Y. Krynetski, T. Loennechen, M. Y. Fessing, H. L. Tai, C. H. Pui, M. V. Relling, and W. E. Evans. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance [see comments]. Ann. Intern. Med. 126:608-614 (1997).
16. 16. R. Honchel, I. A. Aksoy, C. Szumlanski, T. C. Wood, D. M. Otterness, E. D. Wieben, and R. M. Weinshilboum. Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol. Pharmacol. 43:878-887 (1993).
17. 17. M. Fessing, V. M. Belkov, E. Y. Krynetski, and W. E. Evans. Molecular cloning and functional characterization of the cDNA encoding the murine thiopurine S-methyltransferase (TPMT). FEBS Letters 424:143-145 (1998).
18. 18. B. Cournoyr, S. Watanabe, and A. Vivian. A tellurite-resistance genetic determinant from phytopathogenic pseudomonads encodes a thiopurine methyltransferase: evidence of a widely-conserved family of methyltransferases. Biochim. Biophys. Acta 1397:161-167 (1998).
19. 19. J. W. Doran. Microorganisms and the biological cycling of Selenium. Adv. Microbiol. Ecol. 6:1-32 (1982).
20. 20. W. E. Evans, M. Horner, Y. Q. Chu, D. Kalwinsky, and W. M. Roberts. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119:985-989 (1991).
21. 21. L. Lennard, B. E. Gibson, T. Nicole, and J. S. Lilleyman. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch. Dis. Child 69:577-579 (1993).
22. 22. L. Lennard, J. A. Van Loon, and R. M. Weinshilboum. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46:149-154 (1989).
23. 23. E. Schutz, J. Gummert, F. Mohr, and M. Oellerich. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [letter] [see comments]. Lancet 341:436 (1993).
24. 24. L. Lennard and J. S. Lilleyman. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia [published erratum appears in J. Clin. Oncol. 1990 Mar;8(3):567]. J. Clin. Oncol. 7:1816-1823 (1989).
25. 25. L. Lennard, J. S. Lilleyman, J. Van Loon, and R. M. Weinshilboum. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225-229 (1990).
26. 26. H. L. McLeod, D. R. Miller, and W. E. Evans. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [letter; comment]. Lancet 341:1151 (1993).
27. 27. M. V. Relling, Q. Lui, C. H. Pui, and W. E. Evans. Are patients with intermediate TPMT activity (e.g. heterozygous genotypes and phenotypes) at intermediate risk of thiopurine hematopoietic toxicity? Second Thiopurine Symp. (Abstract) (1996).
28. 28. A. Black, H. L. McLeod, H. A. Capell, R. H. Powrie, L. K. Matowe, S. C. Pritchard, E. S. R. Collie-Duguid, and D. M. Reid. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129:716-718 (1998).
29. 29. P. R. Chocair, J. A. Duley, H. A. Simmonds, and J. S. Cameron. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53:1051-1056 (1992).
30. 30. R. Pieters, D. R. Huismans, A. H. Loonen, G. J. Peters, K. Hahlen, A. Van Der Does-Van Den Berg, E. R. Van Wering, and A. J. Veerman. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int. J. Cancer 51:213-217 (1992).
31. 31. E. Y. Krynetski, N. F. Krynetskaia, Y. Yanishevski, and W. E. Evans. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol. Pharmacol. 47:1141-1147 (1995).
32. 32. L. Lennard, D. Keen, and J. S. Lilleyman. Oral 6-mercaplopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin. Pharmacol. Ther. 40:287-292 (1986).
33. 33. G. Leipold, E. Schutz, and M. Oellerich. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthitis. Arthritis and Rheumatism 40:1896-1898 (1997).
34. 34. E. Y. Krynetski, J. D. Schuetz, A. J. Galpin, C. H. Pui, M. V. Relling, and W. E. Evans. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. U.S.A. 92:949-953 (1995).
35. 35. H. L. Tai, E. Y. Krynetski, C. R. Yates, T. Loennechen, M. Y. Fessing, N. F. Krynetskaia, and W. E. Evans. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 58:694-702 (1996).
36. 36. C. Szumlanski, D. Otterness, C. Her, D. Lee, B. Brandriff, D. Kelsell, N. Spurr, L. Lennard, E. Wieben, and R. Weinshilboum. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15:17-30 (1996).
37. 37. D. Otterness, C. Szumlanski, L. Lennard, B. Klemetsdal, J. Aarbakke, J. O. Park-Hah, H. Iven, K. Schmiegelow, E. Branum, J. O'Brien, and R. Weinshilboum. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62:60-73 (1997).
38. 38. C. Spire-Vayrone de la Mourneyre, H. Debuysere, N. Sabbagh, D. Marez, E. Vinner, E. D. Chevalier, J. M. Lo Guidice, and F. Broly. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Human Mutation 12:177-185 (1998).
39. 39. H. L. Tai, E. Y. Krynetski, E. G. Schuetz, Y. Yanishevski, and W. E. Evans. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. U.S.A. 94:6444-6449 (1997).
40. 40. H. L. McLeod, E. Y. Krynetski, J. A. Wilimas, and W. E. Evans. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 5:281-286 (1995).
41. 41. G. M. Pacifici, P. Romiti, L. Giuliani, and A. Raner. Thiopurine methyltransferase in humans: development and tissue distribution. Develop. Pharmacol. Ther. 17:16-23 (1991).
42. 42. P. A. Pazmino, S. L. Sladek, and R. M. Weinshilboum. Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin. Pharmacol. Ther. 28:356-367 (1980).
43. 43. D. Lee, C. Szumlanski, J. Houtman, R. Honchel, K. Rojas, J. Overhauser, E. D. Wieben, and R. M. Weinshilboum. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab. Dispos. 23:398-405 (1995).
44. 44. T. Loennechen, C. R. Yates, M. Fessing, M. V. Relling, E. Y. Krynetski, and W. E. Evans. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin. Phar. Ther. 64:46-51 (1998).
45. 45. H.-L. Tai, M. Y. Fessing, E. J. Bonten, Y. Yanishevsky, S. D'Azzo, E. Y. Krynetski, and W. E. Evans. Enhanced proteosomal degradation of mutant thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT-deficiency inherited by the mutant human TPMT*2 and TPMT*3 alleles. Pharmacogen. (submitted) (1999).
46. 46. Y. Y. Hon, M. Y. Fessing, C.-H. Pui, M. V. Relling, E. Y. Krynetski, and W. E. Evans. Polymorphism of the thiopurine S-methyltransferase (TPMT) gene in african-americans. Hum. Mol. Genet. (in press) (1999).
47. 47. E. S. R. Collie-Duguid, S. C. Prichard, R. H. Powrie, J. Sludden, D. A. Collier, T. Li, and H. L. McLeod. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and asian populations. Pharmacogenetics (in press) (1998).
48. 48. R. M. Weinshilboum, F. A. Raymond, and P. A. Pazmino. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin. Chim. Acta 85:323-333 (1978).
49. 49. L. C. Woodson, J. H. Dunnette, and R. M. Weinshilboum. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J. Pharmacol. Exp. Ther. 222:174-181 (1982).
50. 50. J. A Van Loon and R. M. Weinshilboum. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem. Genet. 20:637-658 (1982).
51. 51. H. L. McLeod, M. V. Relling, Q. Liu, C.-H. Pui, and W. E. Evans. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897-1902 (1995).
52. 52. A. A. M. Hollander, J. L. C. M. van Saase, A. M. M. Kootte, W. T. van Dorp, H. J. van Bockel, L. A. van Es, and F. J. van der Woude. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 345:610-614 (1995).
53. 53. W. E. Evans, M. V. Relling, A. Rahman, H. L. McLeod, E. P. Scott, and J. S. Lin. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J. Clin. Invest. 91:2150-2154 (1993).
54. 54. F. J. Gonzalez, R. C. Skoda, S. Kimura, M. Umeno, U. M. Zanger, D. W. Nebert, H. V. Gelboin, J. P. Hardwick, and U. A. Meyer. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-446 (1988).
55. 55. D. Marez, M. Legrand, N. Sabbagh, J. M. Lo Giudice, C. Spire, J. J. Lafitte, U. A. Meyer, and F. Broly. Polymorphism of the Cytochrome P450 CYP2D6 gene in the european population: characterization of 48 mutations and 53 alleles. Proceedings of the 12th Int. Symposium on Microsomes and Drug Oxidations 184(Abstract) (1998).
56. 56. W. E. Evans, M. V. Relling, L. H. Rodman, W. R. Crom, J. M. Boyett, and Ching-Hon Pui. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338:499-505 (1998).